| Literature DB >> 35268467 |
Marion Trouillard1, William Dupuis1, Hélène Siaudeau1, Florian Denou1, Emmanuelle Longeau1, Maxime Léger1, Myriam Ammi2, Cyril Sargentini1, Sigismond Lasocki1, Emmanuel Rineau1.
Abstract
Various regional anesthesia (RA) techniques were shown to reduce pain after lung surgery, but controversies remain regarding the best technique to use to improve recovery. In this observational prospective study, the aim was to assess the efficacy of an RA strategy depending on the surgical approach. Patients who underwent lung surgery were included if an RA was planned following our unit procedure (erector spinae plane block (ESP) for video-assisted thoracic surgery (VATS) and thoracic epidural analgesia (TEA) or intrathecal analgesia (IA) for thoracotomy). Patients were compared according to the RA used. In total, 116 patients were included, 70 (60%), 32 (28%), 14 (12%) in the ESP, TEA and IA groups, respectively. Between Day 1 and Day 3, median NRS values were ≤4 at rest, and <50% patients experienced moderate-to-severe pain in each group. There were no significant differences in opioid consumption and in pain at rest or during chest physiotherapy on Days 1 and 2 between groups. However, patients who received an IA had lower NRS than other groups on Day 0 and 3 and a shorter length of hospital stay in comparison with those who received a TEA. Thus, in our institution, a strategy combining ESP for VATS and TEA, or IA for thoracotomy, allowed for effective analgesia after a lung resection. Interestingly, IA appeared to be more effective than TEA in reducing the length of hospital stay and pain on Day 0 and 3.Entities:
Keywords: epidural analgesia; erector spinae plane block; intrathecal analgesia; lung surgery; postoperative pain; postoperative recovery; thoracotomy; video-assisted thoracic surgery
Year: 2022 PMID: 35268467 PMCID: PMC8911238 DOI: 10.3390/jcm11051376
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Choice procedure for the regional anesthesia technique to use in lung surgery at Angers University Hospital, France.
Preoperative characteristics.
| All Patients | ESP Group | TEA Group | IA Group |
| |
|---|---|---|---|---|---|
|
| |||||
| Age (years) | 64 (11) | 64 (11) | 63 (10) | 66 (12) | 0.48 |
| Male | 73 (63%) | 41 (59%) | 21 (66%) | 11 (79%) | 0.32 |
| Height (cm) | 169 (9) | 169 (9) | 169 (8) | 170 (10) | 0.76 |
| Weight (kg) | 72 (17) | 70 (16) | 72 (18) | 81 (22) | 0.16 |
| ASA status | |||||
| I | 5 (4%) | 2 (3%) | 2 (6%) | 1 (7%) | 0.64 |
| II | 47 (41%) | 28 (40%) | 14 (44%) | 5 (36%) | 0.87 |
| III | 63 (54%) | 39 (56%) | 16 (50%) | 8 (57%) | 0.84 |
| IV | 1 (9%) | 1 (1%) | 0 | 0 | 0.72 |
|
| |||||
| COPD | 39 (34%) | 19 (27%) | 16 (50%) | 4 (29%) | 0.08 |
| Active smokers | 27 (23%) | 16 (23%) | 7 (22%) | 4 (29%) | 0.88 |
| Previous thoracic surgery | 24 (21%) | 13 (19%) | 8 (25%) | 3 (21%) | 0.76 |
| Previous thoracic radiotherapy | 10 (9%) | 6 (9%) | 3 (9%) | 1 (7%) | 0.97 |
| Diabetes | 18 (16%) | 12 (17%) | 5 (16%) | 1 (7%) | 0.59 |
| Chronic alcoholism | 15 (13%) | 10 (14%) | 4 (12%) | 1 (7%) | 0.74 |
| Psychiatric disease | 8 (7%) | 4 (6%) | 3 (9%) | 1 (7%) | 0.80 |
| Chronic pain | 24 (21%) | 16 (23%) | 5 (16%) | 3 (21%) | 0.69 |
|
| |||||
| FEV1 (L) | 2.4 (1.9–2.9) | 2.5 (1.9–3.0) | 2.4 (1.8–2.8) | 2.0 (1.8–3.1) | 0.36 |
| Tiffeneau index | 71 (61–79) | 71 (63–80) | 66 (57–78) | 69 (60–78) | 0.28 |
|
| |||||
| Diagnostic biopsy | 5 (4%) | 4 (6%) | 0 | 1 (7%) | 0.36 |
| Lung infection | 2 (2%) | 1 (1%) | 0 | 1 (7%) | 0.22 |
| Tumour resection | 107 (92%) | 65 (93%) | 30 (93%) | 12 (86%) | 0.62 |
| Other | 2 (2%) | 0 | 2 (6%) | 0 | 0.07 |
Values are expressed as numbers (%), mean (standard deviation) or median (IQ 25–75%): ESP, erector spinae plane block; IA, intrathecal analgesia; TEA, thoracic epidural analgesia.
Intraoperative anesthetic and surgical data.
| All Patients | ESP Group | TEA Group | IA Group | ESP vs. TEA | ESP vs. IA | TEA vs. IA | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Remifentanil (mg) | 1.6 (1.0–2.0) | 1.5 (0.9–1.9) | 1.8 (1.4–2.6) | 2.0 (1.5–2.6) | <0.01 | 0.01 | 0.74 |
| Propofol (g) | 1.7 (1.4–2.4) | 1.6 (1.3–2.3) | 1.9 (1.5–2.5) | 2.2 (1.6–3.2) | 0.07 | 0.01 | 0.24 |
|
| 4 (4–5) | 4 (4–5) | 4 (4–5) | 5 (3.75–5.25) | 0.57 | 0.9 | 0.69 |
| Paracetamol | 113 (97%) | 69 (98%) | 30 (94%) | 14 (100%) | 0.23 | 1 | 1 |
| Nefopam | 70 (60%) | 43 (61%) | 19 (59%) | 8 (57%) | 1 | 0.77 | 1 |
| NSAIDs | 22 (19%) | 18 (26%) | 2 (6%) | 2 (14%) | 0.03 | 0.5 | 0.57 |
| Ketamine | 78 (67%) | 52 (74%) | 23 (72%) | 3 (21%) | 0.81 | <0.01 | <0.01 |
|
| |||||||
| Primary thoracotomy | 38 (33%) | 3 (4%) | 27 (84%) | 8 (57%) | <0.01 | <0.01 | 0.24 |
| Converted VATS | 8 (7%) | 3 (4%) | 0 | 1 (%) | 0.55 | 0.52 | 0.3 |
| Not converted VATS | 70 (60%) | 64 (91%) | 5 (16%) | 5 (%) | <0.01 | <0.01 | 0.24 |
|
| |||||||
| Lobectomy | 69 (59%) | 37 (53%) | 23 (72%) | 9 (64%) | <0.01 | 0.24 | 0.17 |
| Pneumonectomy | 7 (6%) | 0 | 6 (19%) | 1 (7%) | <0.01 | 0.16 | 0.65 |
| Segmentectomy | 7 (6%) | 7 (10%) | 0 | 0 | 0.33 | 1 | 0.41 |
| Wedge | 32 (28%) | 26 (37%) | 2 (6%) | 4 (29%) | 0.26 | 1 | 0.49 |
| Biopsy | 1 (8%) | 0 | 1 (3%) | 0 | <0.01 | 0.02 | 0.4 |
|
| 80 (69%) | 43 (61%) | 26 (81%) | 11 (79%) | 0.06 | 0.3 | 1 |
|
| 1 (1–2) | 1 (1–1) | 2 (1–2) | 1.5 (1–2) | <0.01 | 0.01 | 0.57 |
|
| 4 (3%) | 1 (1%) | 3 (9%) | 0 | 0.09 | 1 | 0.54 |
|
| 173 (134–210) | 170 (129–204) | 191 (143–238) | 170 (150–219) | 0.03 | 0.44 | 0.42 |
|
| 131 (114–169) | 132 (120–165) | 120 (84–256) | 131 (67–195) | 0.39 | 0.7 | 0.88 |
Values are expressed as numbers (%) or median (IQ 25–75%): ESP, erector spinae plane block; IA, intrathecal analgesia; NSAIDs, non-steroidal anti-inflammatory drugs; PACU, post-anesthesia care unit; TEA, thoracic epidural analgesia; VATS, video-assisted thoracoscopic surgery.
Figure 2Postoperative pain in the three groups: (A) pain at rest; (B) pain during mobilization (during chest physiotherapy for Days 1 to 3); (C) percentage of patients with a moderate-to-severe pain (NRS ≥ 4). Points with blue line, ESP group; squares with orange line, TEA group; triangle with green line, IA group. The charts A and B show medians and (25–75%) interquartile range, and the chart C shows percentages. *, p < 0.05 between ESP and IA groups; #, p < 0.05 between TEA and IA groups; §, p < 0.05 between ESP and TEA groups. ESP, erector spinae plane block; IA, intrathecal analgesia; TEA, thoracic epidural analgesia; NRS, numerical rating scale of the pain; PACU, post-anesthesia care unit.
Postoperative pain and opioid consumption.
| All Patients | ESP Group | TEA Group | IA Group | ESP vs. TEA | ESP vs. IA | TEA vs. IA | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Day 0 | 115 (99%) | 70 (100%) | 31 (97%) | 14 (100%) | 0.31 | 1 | 1 |
| Day 1 | 95 (82%) | 64 (91%) | 19 (59%) | 12 (86%) | <0.01 | 0.61 | 0.09 |
| Day 2 | 84 (72%) | 50 (71%) | 24 (75%) | 10 (71%) | 0.81 | 1 | 1.0 |
| Day 3 | 69 (59%) | 38 (54%) | 23 (71%) | 8 (57%) | 0.12 | 1 | 0.49 |
|
| |||||||
| H2 | 3 (0–7) | 5 (0–8) | 0 (0–3.5) | 0 (0–4.5) | <0.01 | 0.03 | 0.97 |
| Day 0 | 14 (5–25) | 16 (7–25) | 10 (0–27) | 16 (5–33) | 0.16 | 0.94 | 0.46 |
| Day 1 | 12.3 (2.5–23.3) | 12 (6.5–22) | 6.5 (0–35) | 16 (6–24.5) | 0.31 | 0.6 | 0.49 |
| Day 2 | 10 (0–14.1) | 8.8 (0–12.5) | 11 (0.3–29.5) | 7.5 (0–16.3) | 0.05 | 0.69 | 0.28 |
| Day 3 | 5 (0–10) | 5 (0–10) | 10 (0–18) | 2.75 (0–10) | <0.01 | 0.9 | 0.049 |
| Total | 44 (28.9–73.3) | 44 (28.9–73.3) | 41 (18–94.9) | 57 (19.1–77.1) | 0.96 | 0.80 | 0.86 |
Values are expressed as numbers (%) or median (IQ 25–75%). ESP, erector spinae plane block; IA, intrathecal analgesia; TEA, thoracic epidural analgesia.
Postoperative recovery parameters.
| All Patients | ESP Group | TEA Group | IA Group | ESP vs. TEA | ESP vs. IA | TEA vs. IA | |
|---|---|---|---|---|---|---|---|
|
| 1 (1–1) | 1 (1–1) | 1 (1–1) | 1 (1–1) | 0.02 | 0.18 | 0.49 |
|
| 1 (1–1) | 1 (1–1) | 1 (1–2) | 1 (1–2) | <0.01 | 0.01 | 0.94 |
|
| 68 59%) | 52 (74%) | 9 (28%) | 7 (50%) | <0.01 | 0.1 | 0.18 |
|
| 76 (66%) | 39 (93%) | 25 (78%) | 12 (92%) | 0.09 | 1 | 0.4 |
|
| |||||||
| Day 1 | 35 (25–46) | 37 (27–47) | 35 (27–43) | 25 (21–47) | 0.62 | 0.37 | 0.44 |
| Day 2 | 30 (24–38) | 28 (24–40) | 31 (21–35) | 31 (24–38) | 0.8 | 0.8 | 0.6 |
| Day 3 | 37 (27–46) | 41 (29–46) | 31 (17–54) | 34 (29–53) | 0.19 | 0.7 | 0.42 |
|
| 93 (80%) | 47 (67%) | 32 (100%) | 14 (100%) | <0.01 | <0.01 | 1 |
|
| 2 (1–4) | 1 (0–2) | 4 (3–6) | 1 (1–2.5) | <0.01 | <0.01 | <0.01 |
|
| 5 (3–9) | 4 (3–5) | 10 (6–15) | 6 (4–11) | <0.01 | 0.07 | 0.046 |
Values are expressed as numbers (%) or median (IQ 25–75%). ESP, erector spinae plane block; IA, intrathecal analgesia; ICU, Intensive care unit; PEF, Peak expiratory flow; TEA, thoracic epidural analgesia.